Known targets — ChEMBL curated mechanism
FGFR1FGFR2FGFR3FGFR4FLT1FLT4KDRPDGFRAPDGFRB
The experimentally established mechanism targets of Piminodine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 2/20 | 0.64 |
| ▸ | OPRM1 | P35372 | 9/20 | 0.64 |
| ▸ | OPRD1 | P41143 | 8/20 | 0.64 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.64 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piminodine SCHEMBL1286844 | 0.97 | KCNA3 (0.66) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| Piminodine SCHEMBL26477 | 0.95 | KCNA3 (0.71) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL11708747 | 0.81 | KCNA3 (0.80) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL6197539 | 0.80 | KCNA3 (0.77) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL11712840 | 0.79 | OPRM1 (0.82) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL7313939 | 0.79 | KCNA3 (1.00) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| Hydrochloric Acid SCHEMBL9064512 | 0.79 | OPRM1 (0.75) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL11601769 | 0.78 | OPRM1 (0.80) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL9064841 | 0.78 | KCNA3 (0.73) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL11712071 | 0.78 | OPRM1 (1.00) | KCNA3OPRM1OPRD1OPRK1SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108473949-A | The purposes of candidate stem cell/progenitor cell populations of amplification | 弗莱德哈钦森癌症研究中心 | 2018-08-31 | — | — | CN | claimed |
| CN-103167800-A | Ready-to-use ketorolac injection | RTU PHARMACEUTICALS LLC | 2013-06-19 | — | — | CN | claimed |
| CN-1780611-B | Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer | PURDUE PHARMA LTD | 2013-01-30 | — | — | CN | claimed |
| CN-1938004-B | Tamper resistant dosage form comprising an adsorbent and an adverse agent | EURO-CELTIQUE S.A. (LU) | 2011-12-21 | — | — | CN | claimed |
| CN-102159193-A | Pharmaceutical dosage form comprising poly (epsilon-caprolactone) | PURDUE PHARMA LP | 2011-08-17 | — | — | CN | claimed |
| CN-1938004-A | Tamper resistant dosage form comprising an adsorbent and an adverse agent | EURO CELTIQUE SA (LU) | 2007-03-28 | — | — | CN | claimed |
| CN-1267087-C | Pharmaceutical tablet | PHARMACIA CORP (US) | 2006-08-02 | — | — | CN | claimed |
| CN-1780611-A | Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer | PURDUE PHARMA LTD (US) | 2006-05-31 | — | — | CN | claimed |
| CN-1630512-A | Pharmaceutical tablet | PHARMACIA CORP (US) | 2005-06-22 | — | — | CN | claimed |
| CN-1130352-A | Method for relieving pain by orally administering 24-hour sustained-release opioid dosage form capable of rapidly increasing initial blood concentration of patient | EURO CELTIQUE SA (LU) | 1996-09-04 | — | — | CN | claimed |
| US-12590054-B2 | Use of D9-methadone for postoperative pain relief | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-03-31 | — | — | US | disclosed |
| US-20240116851-A1 | USE OF D9-METHADONE FOR POSTOPERATIVE PAIN RELIEF | UNIV TEXAS (US) | 2024-04-11 | — | — | US | disclosed |
| CN-105874332-B | diagnosis and treatment of autoimmune diseases | 戴埃克斯有限公司 | 2019-11-12 | — | — | CN | disclosed |
| CN-109475505-A | Peroral dosage form with pharmaceutical compositions, barrier layer and medicine layer | 度瑞公司 | 2019-03-15 | — | — | CN | disclosed |
| CN-105209012-B | Drug delivery device and method for drug delivery | 塔里斯生物医药公司 | 2019-02-01 | — | — | CN | disclosed |
| US-4067774-A | Compounds for enzyme amplification assay | SYVA COMPANY (US) | 1978-01-10 | — | — | US | disclosed |
| US-3975237-A | LIGANDS | SYVA COMPANY (US) | 1976-08-17 | — | — | US | disclosed |
| US-3966764-A | ELECTRON SPIN RESONANCE | SYVA COMPANY (US) | 1976-06-29 | — | — | US | disclosed |
| US-3966556-A | Compounds for enzyme amplification assay methadone analogs | SYVA COMPANY (US) | 1976-06-29 | — | — | US | disclosed |
| US-3966744-A | Spin labeled compounds | SYVA COMPANY (US) | 1976-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116851-A1 | USE OF D9-METHADONE FOR POSTOPERATIVE PAIN RELIEF | OPRM1, OPRD1, OPRK1 | KCNA3 470/4885OPRM1 1/4885OPRD1 2/4885 |
| US-12590054-B2 | Use of D9-methadone for postoperative pain relief | OPRM1, OPRD1, OPRK1 | KCNA3 899/4885OPRM1 1/4885OPRD1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.